Research Reports | Market Assessment
April 2015

Renal Cell Carcinoma (First-Line Advanced/Metastatic) | Decision Base | US | 2015

What Attributes Will Distinguish Emerging Therapies, According to Physicians and Payers?

Targeted therapies, particularly tyrosine kinase inhibitors (TKIs) that target angiogenesis, dominate the treatment of advanced/metastatic renal cell carcinoma (RCC) in the first line. While mTOR inhibitors such as temsirolimus (Pfizer’s Torisel) have expanded the treatment options for patients in this setting, especially those with poor-prognosis disease, RCC remains incurable, and most first-line patients relapse following treatment. Significant clinical and commercial opportunities remain for new therapies that can provide greater survival benefits than the currently available agents.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports